# FDA Approves QUAGEN's ANDA Application, Expanding Generic Drug Portfolio QUAGEN has received FDA approval for ANDA216910, strengthening its position in the generic pharmaceuticals market and enabling the company to capture additional market share in an increasingly competitive landscape. The approval demonstrates QUAGEN's continued investment in generic drug development and positions the company to address patient access while generating revenue from an expanded product portfolio.